Skip to main content
Clinical Trials/NCT06186934
NCT06186934
Recruiting
Not Applicable

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

Kyowa Kirin Korea Co., Ltd.1 site in 1 country600 target enrollmentDecember 21, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyperphosphatemia
Sponsor
Kyowa Kirin Korea Co., Ltd.
Enrollment
600
Locations
1
Primary Endpoint
Serum phosphorus levels
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings

Registry
clinicaltrials.gov
Start Date
December 21, 2023
End Date
January 30, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults 19 years of age or older
  • CKD patients undergoing hemodialysis to whom Nephoxil capsule administration is deemed necessary for improvement of hyperphosphatemia as per the determination of the investigator
  • Patients who received Nephoxil capsule for the first time according to the national approval after conclusion of the contract with the study institution
  • Those (or his / her legal guardian) who have agreed in writing to participate in the survey

Exclusion Criteria

  • Patients with contraindications to receive Nephoxil
  • Patients with hypersensitivity to the active substance or to any of the excipients
  • Patients with hypophosphatemia
  • Patients with abnormal iron metabolism or symptoms of excessive iron (e.g. hemochromatosis)
  • Patients who intend to use this drug for non-approved indications
  • Patients who participated in pre-market clinical trials with Nephoxil
  • Patients who took this drug before the starting day of this survey

Outcomes

Primary Outcomes

Serum phosphorus levels

Time Frame: 8 weeks

Effectiveness evaluation is performed based on Serum phosphorus levels (mg/dL) before and after Nephoxil administration. We collect the most recent measurements prior to the initial administration, and measurements after at least four and eight weeks of administration of Nephoxil

Study Sites (1)

Loading locations...

Similar Trials